{"timestamp": "2026-01-18T19:44:40.411037", "question": "{}", "final_output": "Final Assessment:\nAdvanced recurrent pelvic malignancy with progressive pelvic, hepatic, and iliac bone disease and significant cytopenias; primary histology, prior treatments, and goals of care remain undefined, so only diagnostic and supportive steps are appropriate today. [@2022-12-29|MR][@2022-12-29|CT][@20230103|5600862]\n\nCore Treatment Strategy:\n- Urgently retrieve all pathology, operative notes, and full oncology records to define diagnosis, prior lines, and treatment intent (unknown/needs update).  \n- Arrange focused workup and management of anemia/lymphopenia, including transfusion needs, before any cytotoxic or intensive therapy. [@20230103|5600862]  \n- Document detailed performance status and symptom burden to guide feasibility of systemic, radiotherapy, or best-supportive-care–dominant strategies. (unknown/needs update)  \n- Consider updated cross-sectional imaging and PET/FDG only if, after diagnosis/intent clarification, results would change systemic vs palliative/RT planning. [@2022-12-29|MR][@2022-12-29|CT][@guideline:nccn_ovariancancer_v3_2025__v00000000|14]\n\nChange Triggers:\n- If pathology and prior treatment history confirm a specific gynecologic primary and line of therapy, reconvene MDT to select systemic/RT approach.  \n- If performance status or cytopenias prove poor or non-correctable, shift emphasis toward symptom-directed palliative care over disease-directed intensification.", "initial_ops": {"chair": "- Advanced recurrent pelvic malignancy with progressive liver and bone metastases; clarify primary site, histology, and prior treatments before systemic strategy.  \n\n- Marked anemia and lymphopenia; urgently evaluate etiology, bleeding, iron/B12/folate, hemolysis, and performance status before intensive therapy. [@20230103|2023-01-03]  \n\n- HRD negative, BRCA wild-type; consider non‑PARP systemic/locoregional options once pathology, stage, symptoms, and goals of care are updated. [@OH2203828|2022-04-18]", "oncologist": "- Diagnosis, stage, prior systemic therapy line, and treatment intent are all unknown/needs update before any regimen choice.  \n\n- Current labs show significant anemia with preserved platelets and renal/liver function, affecting intensity and timing of systemic therapy [@20221229|8300002][@20230103|5600862].  \n\n- Germline testing: HRD negative, no pathogenic BRCA1/2 or other listed DNA-repair mutations; influences maintenance/targeted strategy selection [@OH2203828|2022-04-18].", "radiologist": "- Liver: multiple low-density metastases, increased number and size versus 2022-10-24; largest ~17×14 mm. [@2022-10-24|CT][@2022-12-29|CT]\n\n- Pelvis: presacral mass ~53×44 mm with heterogeneous enhancement, involving adjacent peritoneum and sacrum; pelvic mesenteric nodules. [@2022-12-29|MR]\n\n- New right iliac bone enhancing lesion suggesting osseous metastasis; rectal wall thickening/enhancement may indicate local invasion. [@2022-12-29|MR]", "pathologist": "- No histology, grade, or IHC available; need primary pathology report and any subsequent biopsies for definitive diagnosis/grading (unknown/needs update).\n\n- Molecular: germline ATM exon8 c.A947G:p.Y316C variant; HRD, BRCA1/2, TP53, ARID1A, PTEN, PIK3CA, PALB2, RAD51D, BRIP1, BARD1 all negative [@OH2203828|2022-04-18].\n\n- Somatic tumor sequencing, HRD status on tumor tissue, and current stage/site of disease not documented; require updated tumor NGS/IHC reports (unknown/needs update).", "nuclear": "- No PET/FDG study available; metabolic pattern, staging impact, and recurrence assessment are currently unknown/needs update.\n\n- Cross‑sectional imaging shows progressive multifocal hepatic lesions, highly suspicious for metastases, but without metabolic characterization [@2022-10-24|CT][@2022-12-29|CT].\n\n- Pelvic MR shows enlarging presacral mass with adjacent bone/peritoneal involvement, compatible with local recurrence and metastasis, pending PET correlation [@2022-12-29|MR]."}, "merged_summary": "Key Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and likely rectal wall.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no HRD/BRCA-based options.\n- Staging based on CT/MR only; no PET/FDG performed.\n- Key management decisions are currently being considered without a confirmed tissue diagnosis.\n\nControversies:\n- Primary site, histologic subtype, and grade remain undefined; true origin of pelvic malignancy unclear.\n- Treatment intent and prior systemic therapy lines unknown, limiting systemic and local strategy planning.\n- Appropriateness and timing of systemic vs palliative/locoregional interventions in context of cytopenias and metastatic burden remain uncertain.\n- Whether PET/FDG would meaningfully alter management or radiotherapy planning is not yet established.\n\nMissing Info:\n- Pathology: original and metastatic biopsy reports, full IHC panel, and tumor grade.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, toxicities, and current symptoms/performance status.\n- Hematologic workup for anemia/lymphopenia.\n- Tumor-level molecular profiling (somatic NGS, tumor HRD, predictive markers).\n- PET/FDG or equivalent whole-body functional imaging for comprehensive staging.\n\nWorking Plan:\n- Prioritize retrieval and review of all pathology (primary and metastatic), operative notes, and oncology treatment records before further MDT decision-making.\n- Defer selection of a specific systemic regimen and any local/ablative procedures until diagnosis, primary tumor type, and treatment intent are clarified.\n- Complete workup of anemia and lymphopenia and document current performance status and symptom burden.\n- Consider whole-body PET/FDG, with dedicated pelvic and hepatic assessment, if results are expected to change systemic strategy or radiotherapy planning.\n- Reconvene MDT to reassess systemic and locoregional/palliative options once diagnosis, staging, biomarkers, and goals of care are defined.", "final_round_ops": {"Round 1": {"chair": "- Defer new systemic or local oncologic treatments until pathology, prior oncologic history, and performance status are retrieved and reviewed (currently unknown).  \n\n- Urgently investigate anemia and lymphopenia (bleeding, nutritional, marrow, hemolysis) and document ECOG/functional status before planning intensive therapy. [@20230103|2023-01-03]  \n\n- Consider PET/FDG only after diagnosis/intent clarification, if results would alter staging, radiotherapy planning, or systemic vs palliative strategy. [@2022-12-29|2022-12-29]", "oncologist": "- Defer systemic regimen choice; urgently retrieve full pathology, IHC, and prior oncologic treatment history to define diagnosis and line of therapy (unknown/needs update).  \n\n- Investigate anemia and lymphopenia, including causes and transfusion needs, and document performance status before considering further cytotoxic or targeted therapy [@20230103|5600862].  \n\n- Consider PET/FDG for full staging and radiotherapy planning only after pathology confirmation and goals-of-care discussion (unknown/needs update).", "radiologist": "- No new imaging since 2022-12-29; obtain current CT/MR (±PET/FDG) for up-to-date staging and trend. [@2022-12-29|CT][@2022-12-29|MR]  \n\n- Defer planning local/ablative radiologic procedures until pathology, primary tumor type, and treatment intent are clarified. (pathology and history unknown)  \n\n- If PET/FDG performed, ensure whole-body protocol with focused pelvic, hepatic, and right iliac bone assessment for comprehensive disease mapping. (PET/FDG unknown)", "pathologist": "- Retrieve and review all prior pathology (primary and metastatic), IHC, and grading to establish definitive diagnosis (currently unknown/needs update).  \n\n- After diagnosis confirmation, obtain tumor-level molecular testing (somatic NGS, tumor HRD, other markers) if tissue and performance status allow (unknown/needs update).  \n\n- Defer commitment to specific systemic strategies until pathology, oncologic history, and cytopenia workup are clarified and formally documented (unknown/needs update).", "nuclear": "- Recommend whole‑body FDG PET/CT to clarify metabolic burden, confirm recurrence, and assess liver, presacral, and iliac bone lesions [@2022-10-24|CT][@2022-12-29|MR][@2022-12-29|CT].  \n\n- If PET/CT performed, ensure high‑resolution pelvic and hepatic imaging to guide potential radiotherapy fields and avoid missing additional metastases [@2022-12-29|MR][@2022-12-29|CT].  \n\n- PET findings should be integrated with pending pathology and clinical status before altering staging or committing to further locoregional interventions (pathology/PS currently unknown)."}, "Round 2": {"chair": "- Urgently retrieve and review all pathology, operative notes, and oncology records before committing to systemic or local oncologic treatment (currently unknown).  \n\n- Perform targeted workup of anemia/lymphopenia and document ECOG/symptom burden to judge fitness for systemic or radiotherapy approaches. [@20230103|2023-01-03]  \n\n- Consider whole‑body PET/FDG with focused pelvic/hepatic assessment only if clarified goals suggest results would change systemic or radiotherapy planning. [@2022-12-29|2022-12-29]", "oncologist": "- Defer systemic and local/ablative treatment decisions until full pathology (including IHC, grade) and prior oncologic history are obtained (unknown/needs update).  \n\n- Urgently evaluate anemia and lymphopenia, transfusion needs, and document performance status before reconsidering any cytotoxic or targeted systemic strategy [@20230103|2023-01-03].  \n\n- Consider whole-body PET/FDG with focused pelvic/hepatic views only if pathology and goals-of-care review indicate results would change management (unknown/needs update).", "radiologist": "- No imaging newer than 2022-12-29; obtain updated CT/MR (±PET/FDG) for current staging before local procedures. [@2022-12-29|CT][@2022-12-29|MR]  \n\n- Presacral mass with sacral/peritoneal and likely rectal involvement plus progressive liver and iliac bone lesions indicates widespread disease; prioritize palliative intent clarification. [@2022-12-29|MR][@2022-12-29|CT]  \n\n- If PET/FDG pursued, use whole-body protocol with focused pelvic, hepatic, and right iliac bone evaluation to guide radiotherapy/systemic planning. (PET/FDG unknown)", "pathologist": "- Retrieve and review all primary/metastatic pathology reports, IHC, and grading to establish definitive diagnosis (currently unknown/needs update).  \n\n- After diagnosis confirmation, perform tumor-level molecular profiling (somatic NGS, tumor HRD, predictive markers) if tissue available (unknown/needs update).  \n\n- Reconvene MDT to align staging and biomarker data with clarified goals of care before systemic or locoregional decisions (unknown/needs update).", "nuclear": "- No PET/FDG has been performed; metabolic tumor burden, recurrence confirmation, and PET-based staging remain unknown/needs update (CT/MR only) [@2022-12-29|MR][@2022-12-29|CT].  \n\n- If obtained, whole‑body FDG PET/CT could better define liver, presacral, and right iliac bone involvement and detect occult disease [@2022-10-24|CT][@2022-12-29|MR][@2022-12-29|CT].  \n\n- PET findings should be interpreted jointly with pending pathology and performance status before changing radiotherapy fields or overall staging (pathology/PS currently unknown)."}}, "interaction_log": {"Round 1": {"Turn 1": {"chair": {"chair": null, "oncologist": "Before proposing any new systemic plan today, please first clarify prior systemic lines, responses, and current performance status given marked anemia/lymphopenia and progressive metastases.", "radiologist": null, "pathologist": "We urgently need full pathology (primary and any recurrent/metastatic biopsies with IHC/grade) to define tumor type before further treatment decisions.", "nuclear": null}, "oncologist": {"chair": "Systemic regimen choice today is unsafe without knowing primary histology, prior systemic lines, and current performance status; these must be clarified before committing to further cytotoxic or targeted therapy in the setting of marked anemia and progressive metastatic disease.", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": "Imaging demonstrates progressive multifocal liver metastases and enlarging presacral mass with probable sacral and rectal involvement; this suggests advancing systemic and locoregional disease burden needing correlation with current symptoms and performance status.", "radiologist": null, "pathologist": null, "nuclear": "CT/MR show progressive liver, presacral, and new right iliac bone lesions; PET/FDG could refine whole-body staging and detect additional metastases if consistent with goals of care."}, "pathologist": {"chair": "Key management decisions are being discussed without any confirmed tissue diagnosis; MDT planning should be deferred until pathology reports are obtained and reviewed.", "oncologist": "Primary histology, IHC panel, and grade remain completely undocumented; please prioritize retrieving original and metastatic biopsy pathology for diagnostic clarification.", "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": "No PET/FDG has been done; given multifocal liver, pelvic, and bone disease, whole‑body PET could refine current staging and recurrence assessment if results would change management or radiotherapy planning.", "radiologist": "If PET/FDG is obtained, please ensure dedicated pelvic and hepatic assessment to better characterize presacral, hepatic, and iliac bone lesions and detect additional disease.", "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": "Given the absence of any documented tissue diagnosis or prior systemic history, please avoid committing to a specific systemic regimen today and focus on organizing pathology retrieval and anemia/lymphopenia workup.", "radiologist": "Further local or ablative procedures should not be planned until pathology and oncologic history clarify primary tumor type and intent of care.", "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}, "Round 2": {"Turn 1": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}}, "agent_logs": {"chair": [{"role": "chair", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Advanced recurrent pelvic malignancy with progressive liver and bone metastases; clarify primary site, histology, and prior treatments before systemic strategy.  \n\n- Marked anemia and lymphopenia; urgently evaluate etiology, bleeding, iron/B12/folate, hemolysis, and performance status before intensive therapy. [@20230103|2023-01-03]  \n\n- HRD negative, BRCA wild-type; consider non‑PARP systemic/locoregional options once pathology, stage, symptoms, and goals of care are updated. [@OH2203828|2022-04-18]", "timestamp": "2026-01-18T19:42:13.754219"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and probable rectal wall involvement.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no current HRD/BRCA-based options.\n- Staging based only on CT/MR; no PET/FDG performed.\n\nControversies:\n- Primary site, histologic subtype, and grade of the pelvic malignancy remain undefined.\n- Treatment intent and prior systemic therapy lines are unknown, limiting systemic planning.\n- Optimal balance/timing of systemic vs purely palliative/locoregional approaches in the context of cytopenias and metastatic burden is unclear.\n\nMissing Info:\n- Full pathology: primary and recurrent/metastatic biopsy reports, IHC, and grading.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, and toxicities.\n- Detailed anemia/lymphopenia workup and current performance status.\n- Tumor-level molecular data (somatic NGS, tumor HRD, other predictive markers).\n- PET/FDG or equivalent functional imaging for complete staging.\n\nWorking Plan:\n- Obtain and review complete pathology, operative notes, and oncology treatment history to define diagnosis, stage, and treatment line.\n- Perform targeted evaluation of anemia and lymphopenia and document performance status.\n- Consider PET/FDG for full staging if compatible with goals of care.\n- After clarification of diagnosis, stage, biomarkers, and patient goals, re-discuss systemic and locoregional/palliative options (non‑PARP focused given HRD/BRCA-negative status).\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Before proposing any new systemic plan today, please first clarify prior systemic lines, responses, and current performance status given marked anemia/lymphopenia and progressive metastases.\",\"why\":\"safety\"},{\"target\":\"pathologist\",\"message\":\"We urgently need full pathology (primary and any recurrent/metastatic biopsies with IHC/grade) to define tumor type before further treatment decisions.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T19:42:36.225876"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and probable rectal wall involvement.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no current HRD/BRCA-based options.\n- Staging based only on CT/MR; no PET/FDG performed.\n\nControversies:\n- Primary site, histologic subtype, and grade of the pelvic malignancy remain undefined.\n- Treatment intent and prior systemic therapy lines are unknown, limiting systemic planning.\n- Optimal balance/timing of systemic vs purely palliative/locoregional approaches in the context of cytopenias and metastatic burden is unclear.\n\nMissing Info:\n- Full pathology: primary and recurrent/metastatic biopsy reports, IHC, and grading.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, and toxicities.\n- Detailed anemia/lymphopenia workup and current performance status.\n- Tumor-level molecular data (somatic NGS, tumor HRD, other predictive markers).\n- PET/FDG or equivalent functional imaging for complete staging.\n\nWorking Plan:\n- Obtain and review complete pathology, operative notes, and oncology treatment history to define diagnosis, stage, and treatment line.\n- Perform targeted evaluation of anemia and lymphopenia and document performance status.\n- Consider PET/FDG for full staging if compatible with goals of care.\n- After clarification of diagnosis, stage, biomarkers, and patient goals, re-discuss systemic and locoregional/palliative options (non‑PARP focused given HRD/BRCA-negative status).\n[R1T1 DELTA] n with current symptoms and performance status. | pathologist->oncologist(missing): Primary histology, IHC panel, and grade remain completely undocumented; please prioritize retrieving original and metastatic biopsy pathology for diagnostic clarification. | pathologist->chair(safety): Key management decisions are being discussed without any confirmed tissue diagnosis; MDT planning should be deferred until pathology reports are obtained and reviewed. | nuclear->oncologist(missing): No PET/FDG has been done; given multifocal liver, pelvic, and bone disease, whole‑body PET could refine current staging and recurrence assessment if results would change management or radiotherapy planning. | nuclear->radiologist(missing): If PET/FDG is obtained, please ensure dedicated pelvic and hepatic assessment to better characterize presacral, hepatic, and iliac bone lesions and detect additional disease.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Given the absence of any documented tissue diagnosis or prior systemic history, please avoid committing to a specific systemic regimen today and focus on organizing pathology retrieval and anemia/lymphopenia workup.\",\"why\":\"safety\"},{\"target\":\"radiologist\",\"message\":\"Further local or ablative procedures should not be planned until pathology and oncologic history clarify primary tumor type and intent of care.\",\"why\":\"safety\"}]}", "timestamp": "2026-01-18T19:42:46.614932"}, {"role": "chair", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and probable rectal wall involvement.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no current HRD/BRCA-based options.\n- Staging based only on CT/MR; no PET/FDG performed.\n\nControversies:\n- Primary site, histologic subtype, and grade of the pelvic malignancy remain undefined.\n- Treatment intent and prior systemic therapy lines are unknown, limiting systemic planning.\n- Optimal balance/timing of systemic vs purely palliative/locoregional approaches in the context of cytopenias and metastatic burden is unclear.\n\nMissing Info:\n- Full pathology: primary and recurrent/metastatic biopsy reports, IHC, and grading.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, and toxicities.\n- Detailed anemia/lymphopenia workup and current performance status.\n- Tumor-level molecular data (somatic NGS, tumor HRD, other predictive markers).\n- PET/FDG or equivalent functional imaging for complete staging.\n\nWorking Plan:\n- Obtain and review complete pathology, operative notes, and oncology treatment history to define diagnosis, stage, and treatment line.\n- Perform targeted evaluation of anemia and lymphopenia and document performance status.\n- Consider PET/FDG for full staging if compatible with goals of care.\n- After clarification of diagnosis, stage, biomarkers, and patient goals, re-discuss systemic and locoregional/palliative options (non‑PARP focused given HRD/BRCA-negative status).\n[R1T1 DELTA] n with current symptoms and performance status. | pathologist->oncologist(missing): Primary histology, IHC panel, and grade remain completely undocumented; please prioritize retrieving original and metastatic biopsy pathology for diagnostic clarification. | pathologist->chair(safety): Key management decisions are being discussed without any confirmed tissue diagnosis; MDT planning should be deferred until pathology reports are obtained and reviewed. | nuclear->oncologist(missing): No PET/FDG has been done; given multifocal liver, pelvic, and bone disease, whole‑body PET could refine current staging and recurrence assessment if results would change management or radiotherapy planning. | nuclear->radiologist(missing): If PET/FDG is obtained, please ensure dedicated pelvic and hepatic assessment to better characterize presacral, hepatic, and iliac bone lesions and detect additional disease.\n[R1T2 DELTA] chair->oncologist(safety): Given the absence of any documented tissue diagnosis or prior systemic history, please avoid committing to a specific systemic regimen today and focus on organizing pathology retrieval and anemia/lymphopenia workup. | chair->radiologist(safety): Further local or ablative procedures should not be planned until pathology and oncologic history clarify primary tumor type and intent of care.\n\nProvide FINAL refined plan.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Defer new systemic or local oncologic treatments until pathology, prior oncologic history, and performance status are retrieved and reviewed (currently unknown).  \n\n- Urgently investigate anemia and lymphopenia (bleeding, nutritional, marrow, hemolysis) and document ECOG/functional status before planning intensive therapy. [@20230103|2023-01-03]  \n\n- Consider PET/FDG only after diagnosis/intent clarification, if results would alter staging, radiotherapy planning, or systemic vs palliative strategy. [@2022-12-29|2022-12-29]", "timestamp": "2026-01-18T19:42:54.598816"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and likely rectal wall.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no HRD/BRCA-based options.\n- Staging based on CT/MR only; no PET/FDG performed.\n- Key management decisions are currently being considered without a confirmed tissue diagnosis.\n\nControversies:\n- Primary site, histologic subtype, and grade remain undefined; true origin of pelvic malignancy unclear.\n- Treatment intent and prior systemic therapy lines unknown, limiting systemic and local strategy planning.\n- Appropriateness and timing of systemic vs palliative/locoregional interventions in context of cytopenias and metastatic burden remain uncertain.\n- Whether PET/FDG would meaningfully alter management or radiotherapy planning is not yet established.\n\nMissing Info:\n- Pathology: original and metastatic biopsy reports, full IHC panel, and tumor grade.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, toxicities, and current symptoms/performance status.\n- Hematologic workup for anemia/lymphopenia.\n- Tumor-level molecular profiling (somatic NGS, tumor HRD, predictive markers).\n- PET/FDG or equivalent whole-body functional imaging for comprehensive staging.\n\nWorking Plan:\n- Prioritize retrieval and review of all pathology (primary and metastatic), operative notes, and oncology treatment records before further MDT decision-making.\n- Defer selection of a specific systemic regimen and any local/ablative procedures until diagnosis, primary tumor type, and treatment intent are clarified.\n- Complete workup of anemia and lymphopenia and document current performance status and symptom burden.\n- Consider whole-body PET/FDG, with dedicated pelvic and hepatic assessment, if results are expected to change systemic strategy or radiotherapy planning.\n- Reconvene MDT to reassess systemic and locoregional/palliative options once diagnosis, staging, biomarkers, and goals of care are defined.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T19:43:34.672996"}, {"role": "chair", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and likely rectal wall.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no HRD/BRCA-based options.\n- Staging based on CT/MR only; no PET/FDG performed.\n- Key management decisions are currently being considered without a confirmed tissue diagnosis.\n\nControversies:\n- Primary site, histologic subtype, and grade remain undefined; true origin of pelvic malignancy unclear.\n- Treatment intent and prior systemic therapy lines unknown, limiting systemic and local strategy planning.\n- Appropriateness and timing of systemic vs palliative/locoregional interventions in context of cytopenias and metastatic burden remain uncertain.\n- Whether PET/FDG would meaningfully alter management or radiotherapy planning is not yet established.\n\nMissing Info:\n- Pathology: original and metastatic biopsy reports, full IHC panel, and tumor grade.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, toxicities, and current symptoms/performance status.\n- Hematologic workup for anemia/lymphopenia.\n- Tumor-level molecular profiling (somatic NGS, tumor HRD, predictive markers).\n- PET/FDG or equivalent whole-body functional imaging for comprehensive staging.\n\nWorking Plan:\n- Prioritize retrieval and review of all pathology (primary and metastatic), operative notes, and oncology treatment records before further MDT decision-making.\n- Defer selection of a specific systemic regimen and any local/ablative procedures until diagnosis, primary tumor type, and treatment intent are clarified.\n- Complete workup of anemia and lymphopenia and document current performance status and symptom burden.\n- Consider whole-body PET/FDG, with dedicated pelvic and hepatic assessment, if results are expected to change systemic strategy or radiotherapy planning.\n- Reconvene MDT to reassess systemic and locoregional/palliative options once diagnosis, staging, biomarkers, and goals of care are defined.\n\nProvide FINAL refined plan.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Urgently retrieve and review all pathology, operative notes, and oncology records before committing to systemic or local oncologic treatment (currently unknown).  \n\n- Perform targeted workup of anemia/lymphopenia and document ECOG/symptom burden to judge fitness for systemic or radiotherapy approaches. [@20230103|2023-01-03]  \n\n- Consider whole‑body PET/FDG with focused pelvic/hepatic assessment only if clarified goals suggest results would change systemic or radiotherapy planning. [@2022-12-29|2022-12-29]", "timestamp": "2026-01-18T19:43:54.921744"}, {"role": "chair", "user_message": "\nAs the MDT chair for gynecologic oncology, you are seeing the patient at OUTPATIENT TIME: 2023-01-03 08:53:29.260000.\nBased on PATIENT FACTS + MDT discussion + FINAL refined plans from all experts, determine the CURRENT best management plan for this visit.\n\nSTRICT RULES:\n- Any factual statement about past tests/treatments must include [@report_id|date] or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id|page] or [@pubmed:PMID].\n- If you cite guideline/PubMed evidence in Core Treatment Strategy or Change Triggers, include at least one tag in that bullet.\n- If experts disagree, pick the safest plan and state the key uncertainty.\n\n# FINAL REFINED PLANS (All experts, last round)\n{\n  \"Round 1\": {\n    \"chair\": \"- Defer new systemic or local oncologic treatments until pathology, prior oncologic history, and performance status are retrieved and reviewed (currently unknown).  \\n\\n- Urgently investigate anemia and lymphopenia (bleeding, nutritional, marrow, hemolysis) and document ECOG/functional status before planning intensive therapy. [@20230103|2023-01-03]  \\n\\n- Consider PET/FDG only after diagnosis/intent clarification, if results would alter staging, radiotherapy planning, or systemic vs palliative strategy. [@2022-12-29|2022-12-29]\",\n    \"oncologist\": \"- Defer systemic regimen choice; urgently retrieve full pathology, IHC, and prior oncologic treatment history to define diagnosis and line of therapy (unknown/needs update).  \\n\\n- Investigate anemia and lymphopenia, including causes and transfusion needs, and document performance status before considering further cytotoxic or targeted therapy [@20230103|5600862].  \\n\\n- Consider PET/FDG for full staging and radiotherapy planning only after pathology confirmation and goals-of-care discussion (unknown/needs update).\",\n    \"radiologist\": \"- No new imaging since 2022-12-29; obtain current CT/MR (±PET/FDG) for up-to-date staging and trend. [@2022-12-29|CT][@2022-12-29|MR]  \\n\\n- Defer planning local/ablative radiologic procedures until pathology, primary tumor type, and treatment intent are clarified. (pathology and history unknown)  \\n\\n- If PET/FDG performed, ensure whole-body protocol with focused pelvic, hepatic, and right iliac bone assessment for comprehensive disease mapping. (PET/FDG unknown)\",\n    \"pathologist\": \"- Retrieve and review all prior pathology (primary and metastatic), IHC, and grading to establish definitive diagnosis (currently unknown/needs update).  \\n\\n- After diagnosis confirmation, obtain tumor-level molecular testing (somatic NGS, tumor HRD, other markers) if tissue and performance status allow (unknown/needs update).  \\n\\n- Defer commitment to specific systemic strategies until pathology, oncologic history, and cytopenia workup are clarified and formally documented (unknown/needs update).\",\n    \"nuclear\": \"- Recommend whole‑body FDG PET/CT to clarify metabolic burden, confirm recurrence, and assess liver, presacral, and iliac bone lesions [@2022-10-24|CT][@2022-12-29|MR][@2022-12-29|CT].  \\n\\n- If PET/CT performed, ensure high‑resolution pelvic and hepatic imaging to guide potential radiotherapy fields and avoid missing additional metastases [@2022-12-29|MR][@2022-12-29|CT].  \\n\\n- PET findings should be integrated with pending pathology and clinical status before altering staging or committing to further locoregional interventions (pathology/PS currently unknown).\"\n  },\n  \"Round 2\": {\n    \"chair\": \"- Urgently retrieve and review all pathology, operative notes, and oncology records before committing to systemic or local oncologic treatment (currently unknown).  \\n\\n- Perform targeted workup of anemia/lymphopenia and document ECOG/symptom burden to judge fitness for systemic or radiotherapy approaches. [@20230103|2023-01-03]  \\n\\n- Consider whole‑body PET/FDG with focused pelvic/hepatic assessment only if clarified goals suggest results would change systemic or radiotherapy planning. [@2022-12-29|2022-12-29]\",\n    \"oncologist\": \"- Defer systemic and local/ablative treatment decisions until full pathology (including IHC, grade) and prior oncologic history are obtained (unknown/needs update).  \\n\\n- Urgently evaluate anemia and lymphopenia, transfusion needs, and document performance status before reconsidering any cytotoxic or targeted systemic strategy [@20230103|2023-01-03].  \\n\\n- Consider whole-body PET/FDG with focused pelvic/hepatic views only if pathology and goals-of-care review indicate results would change management (unknown/needs update).\",\n    \"radiologist\": \"- No imaging newer than 2022-12-29; obtain updated CT/MR (±PET/FDG) for current staging before local procedures. [@2022-12-29|CT][@2022-12-29|MR]  \\n\\n- Presacral mass with sacral/peritoneal and likely rectal involvement plus progressive liver and iliac bone lesions indicates widespread disease; prioritize palliative intent clarification. [@2022-12-29|MR][@2022-12-29|CT]  \\n\\n- If PET/FDG pursued, use whole-body protocol with focused pelvic, hepatic, and right iliac bone evaluation to guide radiotherapy/systemic planning. (PET/FDG unknown)\",\n    \"pathologist\": \"- Retrieve and review all primary/metastatic pathology reports, IHC, and grading to establish definitive diagnosis (currently unknown/needs update).  \\n\\n- After diagnosis confirmation, perform tumor-level molecular profiling (somatic NGS, tumor HRD, predictive markers) if tissue available (unknown/needs update).  \\n\\n- Reconvene MDT to align staging and biomarker data with clarified goals of care before systemic or locoregional decisions (unknown/needs update).\",\n    \"nuclear\": \"- No PET/FDG has been performed; metabolic tumor burden, recurrence confirmation, and PET-based staging remain unknown/needs update (CT/MR only) [@2022-12-29|MR][@2022-12-29|CT].  \\n\\n- If obtained, whole‑body FDG PET/CT could better define liver, presacral, and right iliac bone involvement and detect occult disease [@2022-10-24|CT][@2022-12-29|MR][@2022-12-29|CT].  \\n\\n- PET findings should be interpreted jointly with pending pathology and performance status before changing radiotherapy fields or overall staging (pathology/PS currently unknown).\"\n  }\n}\n\n# Response Format\nFinal Assessment:\n<1–3 sentences: summarize histology/biology, current disease status, and key uncertainties>\n\nCore Treatment Strategy:\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n\nChange Triggers:\n- < ≤20 words “if X, then adjust management from A to B” >\n- < ≤20 words “if X, then adjust management from A to B” >\n", "assistant_reply": "Final Assessment:\nAdvanced recurrent pelvic malignancy with progressive pelvic, hepatic, and iliac bone disease and significant cytopenias; primary histology, prior treatments, and goals of care remain undefined, so only diagnostic and supportive steps are appropriate today. [@2022-12-29|MR][@2022-12-29|CT][@20230103|5600862]\n\nCore Treatment Strategy:\n- Urgently retrieve all pathology, operative notes, and full oncology records to define diagnosis, prior lines, and treatment intent (unknown/needs update).  \n- Arrange focused workup and management of anemia/lymphopenia, including transfusion needs, before any cytotoxic or intensive therapy. [@20230103|5600862]  \n- Document detailed performance status and symptom burden to guide feasibility of systemic, radiotherapy, or best-supportive-care–dominant strategies. (unknown/needs update)  \n- Consider updated cross-sectional imaging and PET/FDG only if, after diagnosis/intent clarification, results would change systemic vs palliative/RT planning. [@2022-12-29|MR][@2022-12-29|CT][@guideline:nccn_ovariancancer_v3_2025__v00000000|14]\n\nChange Triggers:\n- If pathology and prior treatment history confirm a specific gynecologic primary and line of therapy, reconvene MDT to select systemic/RT approach.  \n- If performance status or cytopenias prove poor or non-correctable, shift emphasis toward symptom-directed palliative care over disease-directed intensification.", "timestamp": "2026-01-18T19:44:40.410644"}], "oncologist": [{"role": "oncologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Diagnosis, stage, prior systemic therapy line, and treatment intent are all unknown/needs update before any regimen choice.  \n\n- Current labs show significant anemia with preserved platelets and renal/liver function, affecting intensity and timing of systemic therapy [@20221229|8300002][@20230103|5600862].  \n\n- Germline testing: HRD negative, no pathogenic BRCA1/2 or other listed DNA-repair mutations; influences maintenance/targeted strategy selection [@OH2203828|2022-04-18].", "timestamp": "2026-01-18T19:42:16.069986"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and probable rectal wall involvement.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no current HRD/BRCA-based options.\n- Staging based only on CT/MR; no PET/FDG performed.\n\nControversies:\n- Primary site, histologic subtype, and grade of the pelvic malignancy remain undefined.\n- Treatment intent and prior systemic therapy lines are unknown, limiting systemic planning.\n- Optimal balance/timing of systemic vs purely palliative/locoregional approaches in the context of cytopenias and metastatic burden is unclear.\n\nMissing Info:\n- Full pathology: primary and recurrent/metastatic biopsy reports, IHC, and grading.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, and toxicities.\n- Detailed anemia/lymphopenia workup and current performance status.\n- Tumor-level molecular data (somatic NGS, tumor HRD, other predictive markers).\n- PET/FDG or equivalent functional imaging for complete staging.\n\nWorking Plan:\n- Obtain and review complete pathology, operative notes, and oncology treatment history to define diagnosis, stage, and treatment line.\n- Perform targeted evaluation of anemia and lymphopenia and document performance status.\n- Consider PET/FDG for full staging if compatible with goals of care.\n- After clarification of diagnosis, stage, biomarkers, and patient goals, re-discuss systemic and locoregional/palliative options (non‑PARP focused given HRD/BRCA-negative status).\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Systemic regimen choice today is unsafe without knowing primary histology, prior systemic lines, and current performance status; these must be clarified before committing to further cytotoxic or targeted therapy in the setting of marked anemia and progressive metastatic disease.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T19:42:38.080754"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and probable rectal wall involvement.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no current HRD/BRCA-based options.\n- Staging based only on CT/MR; no PET/FDG performed.\n\nControversies:\n- Primary site, histologic subtype, and grade of the pelvic malignancy remain undefined.\n- Treatment intent and prior systemic therapy lines are unknown, limiting systemic planning.\n- Optimal balance/timing of systemic vs purely palliative/locoregional approaches in the context of cytopenias and metastatic burden is unclear.\n\nMissing Info:\n- Full pathology: primary and recurrent/metastatic biopsy reports, IHC, and grading.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, and toxicities.\n- Detailed anemia/lymphopenia workup and current performance status.\n- Tumor-level molecular data (somatic NGS, tumor HRD, other predictive markers).\n- PET/FDG or equivalent functional imaging for complete staging.\n\nWorking Plan:\n- Obtain and review complete pathology, operative notes, and oncology treatment history to define diagnosis, stage, and treatment line.\n- Perform targeted evaluation of anemia and lymphopenia and document performance status.\n- Consider PET/FDG for full staging if compatible with goals of care.\n- After clarification of diagnosis, stage, biomarkers, and patient goals, re-discuss systemic and locoregional/palliative options (non‑PARP focused given HRD/BRCA-negative status).\n[R1T1 DELTA] n with current symptoms and performance status. | pathologist->oncologist(missing): Primary histology, IHC panel, and grade remain completely undocumented; please prioritize retrieving original and metastatic biopsy pathology for diagnostic clarification. | pathologist->chair(safety): Key management decisions are being discussed without any confirmed tissue diagnosis; MDT planning should be deferred until pathology reports are obtained and reviewed. | nuclear->oncologist(missing): No PET/FDG has been done; given multifocal liver, pelvic, and bone disease, whole‑body PET could refine current staging and recurrence assessment if results would change management or radiotherapy planning. | nuclear->radiologist(missing): If PET/FDG is obtained, please ensure dedicated pelvic and hepatic assessment to better characterize presacral, hepatic, and iliac bone lesions and detect additional disease.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T19:42:48.223297"}, {"role": "oncologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and probable rectal wall involvement.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no current HRD/BRCA-based options.\n- Staging based only on CT/MR; no PET/FDG performed.\n\nControversies:\n- Primary site, histologic subtype, and grade of the pelvic malignancy remain undefined.\n- Treatment intent and prior systemic therapy lines are unknown, limiting systemic planning.\n- Optimal balance/timing of systemic vs purely palliative/locoregional approaches in the context of cytopenias and metastatic burden is unclear.\n\nMissing Info:\n- Full pathology: primary and recurrent/metastatic biopsy reports, IHC, and grading.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, and toxicities.\n- Detailed anemia/lymphopenia workup and current performance status.\n- Tumor-level molecular data (somatic NGS, tumor HRD, other predictive markers).\n- PET/FDG or equivalent functional imaging for complete staging.\n\nWorking Plan:\n- Obtain and review complete pathology, operative notes, and oncology treatment history to define diagnosis, stage, and treatment line.\n- Perform targeted evaluation of anemia and lymphopenia and document performance status.\n- Consider PET/FDG for full staging if compatible with goals of care.\n- After clarification of diagnosis, stage, biomarkers, and patient goals, re-discuss systemic and locoregional/palliative options (non‑PARP focused given HRD/BRCA-negative status).\n[R1T1 DELTA] n with current symptoms and performance status. | pathologist->oncologist(missing): Primary histology, IHC panel, and grade remain completely undocumented; please prioritize retrieving original and metastatic biopsy pathology for diagnostic clarification. | pathologist->chair(safety): Key management decisions are being discussed without any confirmed tissue diagnosis; MDT planning should be deferred until pathology reports are obtained and reviewed. | nuclear->oncologist(missing): No PET/FDG has been done; given multifocal liver, pelvic, and bone disease, whole‑body PET could refine current staging and recurrence assessment if results would change management or radiotherapy planning. | nuclear->radiologist(missing): If PET/FDG is obtained, please ensure dedicated pelvic and hepatic assessment to better characterize presacral, hepatic, and iliac bone lesions and detect additional disease.\n[R1T2 DELTA] chair->oncologist(safety): Given the absence of any documented tissue diagnosis or prior systemic history, please avoid committing to a specific systemic regimen today and focus on organizing pathology retrieval and anemia/lymphopenia workup. | chair->radiologist(safety): Further local or ablative procedures should not be planned until pathology and oncologic history clarify primary tumor type and intent of care.\n\nProvide FINAL refined plan.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Defer systemic regimen choice; urgently retrieve full pathology, IHC, and prior oncologic treatment history to define diagnosis and line of therapy (unknown/needs update).  \n\n- Investigate anemia and lymphopenia, including causes and transfusion needs, and document performance status before considering further cytotoxic or targeted therapy [@20230103|5600862].  \n\n- Consider PET/FDG for full staging and radiotherapy planning only after pathology confirmation and goals-of-care discussion (unknown/needs update).", "timestamp": "2026-01-18T19:42:56.806398"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and likely rectal wall.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no HRD/BRCA-based options.\n- Staging based on CT/MR only; no PET/FDG performed.\n- Key management decisions are currently being considered without a confirmed tissue diagnosis.\n\nControversies:\n- Primary site, histologic subtype, and grade remain undefined; true origin of pelvic malignancy unclear.\n- Treatment intent and prior systemic therapy lines unknown, limiting systemic and local strategy planning.\n- Appropriateness and timing of systemic vs palliative/locoregional interventions in context of cytopenias and metastatic burden remain uncertain.\n- Whether PET/FDG would meaningfully alter management or radiotherapy planning is not yet established.\n\nMissing Info:\n- Pathology: original and metastatic biopsy reports, full IHC panel, and tumor grade.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, toxicities, and current symptoms/performance status.\n- Hematologic workup for anemia/lymphopenia.\n- Tumor-level molecular profiling (somatic NGS, tumor HRD, predictive markers).\n- PET/FDG or equivalent whole-body functional imaging for comprehensive staging.\n\nWorking Plan:\n- Prioritize retrieval and review of all pathology (primary and metastatic), operative notes, and oncology treatment records before further MDT decision-making.\n- Defer selection of a specific systemic regimen and any local/ablative procedures until diagnosis, primary tumor type, and treatment intent are clarified.\n- Complete workup of anemia and lymphopenia and document current performance status and symptom burden.\n- Consider whole-body PET/FDG, with dedicated pelvic and hepatic assessment, if results are expected to change systemic strategy or radiotherapy planning.\n- Reconvene MDT to reassess systemic and locoregional/palliative options once diagnosis, staging, biomarkers, and goals of care are defined.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T19:43:38.664009"}, {"role": "oncologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and likely rectal wall.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no HRD/BRCA-based options.\n- Staging based on CT/MR only; no PET/FDG performed.\n- Key management decisions are currently being considered without a confirmed tissue diagnosis.\n\nControversies:\n- Primary site, histologic subtype, and grade remain undefined; true origin of pelvic malignancy unclear.\n- Treatment intent and prior systemic therapy lines unknown, limiting systemic and local strategy planning.\n- Appropriateness and timing of systemic vs palliative/locoregional interventions in context of cytopenias and metastatic burden remain uncertain.\n- Whether PET/FDG would meaningfully alter management or radiotherapy planning is not yet established.\n\nMissing Info:\n- Pathology: original and metastatic biopsy reports, full IHC panel, and tumor grade.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, toxicities, and current symptoms/performance status.\n- Hematologic workup for anemia/lymphopenia.\n- Tumor-level molecular profiling (somatic NGS, tumor HRD, predictive markers).\n- PET/FDG or equivalent whole-body functional imaging for comprehensive staging.\n\nWorking Plan:\n- Prioritize retrieval and review of all pathology (primary and metastatic), operative notes, and oncology treatment records before further MDT decision-making.\n- Defer selection of a specific systemic regimen and any local/ablative procedures until diagnosis, primary tumor type, and treatment intent are clarified.\n- Complete workup of anemia and lymphopenia and document current performance status and symptom burden.\n- Consider whole-body PET/FDG, with dedicated pelvic and hepatic assessment, if results are expected to change systemic strategy or radiotherapy planning.\n- Reconvene MDT to reassess systemic and locoregional/palliative options once diagnosis, staging, biomarkers, and goals of care are defined.\n\nProvide FINAL refined plan.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Defer systemic and local/ablative treatment decisions until full pathology (including IHC, grade) and prior oncologic history are obtained (unknown/needs update).  \n\n- Urgently evaluate anemia and lymphopenia, transfusion needs, and document performance status before reconsidering any cytotoxic or targeted systemic strategy [@20230103|2023-01-03].  \n\n- Consider whole-body PET/FDG with focused pelvic/hepatic views only if pathology and goals-of-care review indicate results would change management (unknown/needs update).", "timestamp": "2026-01-18T19:43:57.410528"}], "radiologist": [{"role": "radiologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Liver: multiple low-density metastases, increased number and size versus 2022-10-24; largest ~17×14 mm. [@2022-10-24|CT][@2022-12-29|CT]\n\n- Pelvis: presacral mass ~53×44 mm with heterogeneous enhancement, involving adjacent peritoneum and sacrum; pelvic mesenteric nodules. [@2022-12-29|MR]\n\n- New right iliac bone enhancing lesion suggesting osseous metastasis; rectal wall thickening/enhancement may indicate local invasion. [@2022-12-29|MR]", "timestamp": "2026-01-18T19:42:18.253718"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and probable rectal wall involvement.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no current HRD/BRCA-based options.\n- Staging based only on CT/MR; no PET/FDG performed.\n\nControversies:\n- Primary site, histologic subtype, and grade of the pelvic malignancy remain undefined.\n- Treatment intent and prior systemic therapy lines are unknown, limiting systemic planning.\n- Optimal balance/timing of systemic vs purely palliative/locoregional approaches in the context of cytopenias and metastatic burden is unclear.\n\nMissing Info:\n- Full pathology: primary and recurrent/metastatic biopsy reports, IHC, and grading.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, and toxicities.\n- Detailed anemia/lymphopenia workup and current performance status.\n- Tumor-level molecular data (somatic NGS, tumor HRD, other predictive markers).\n- PET/FDG or equivalent functional imaging for complete staging.\n\nWorking Plan:\n- Obtain and review complete pathology, operative notes, and oncology treatment history to define diagnosis, stage, and treatment line.\n- Perform targeted evaluation of anemia and lymphopenia and document performance status.\n- Consider PET/FDG for full staging if compatible with goals of care.\n- After clarification of diagnosis, stage, biomarkers, and patient goals, re-discuss systemic and locoregional/palliative options (non‑PARP focused given HRD/BRCA-negative status).\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"nuclear\",\"message\":\"CT/MR show progressive liver, presacral, and new right iliac bone lesions; PET/FDG could refine whole-body staging and detect additional metastases if consistent with goals of care.\",\"why\":\"missing\"},{\"target\":\"oncologist\",\"message\":\"Imaging demonstrates progressive multifocal liver metastases and enlarging presacral mass with probable sacral and rectal involvement; this suggests advancing systemic and locoregional disease burden needing correlation with current symptoms and performance status.\",\"why\":\"new\"}]}", "timestamp": "2026-01-18T19:42:40.381274"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and probable rectal wall involvement.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no current HRD/BRCA-based options.\n- Staging based only on CT/MR; no PET/FDG performed.\n\nControversies:\n- Primary site, histologic subtype, and grade of the pelvic malignancy remain undefined.\n- Treatment intent and prior systemic therapy lines are unknown, limiting systemic planning.\n- Optimal balance/timing of systemic vs purely palliative/locoregional approaches in the context of cytopenias and metastatic burden is unclear.\n\nMissing Info:\n- Full pathology: primary and recurrent/metastatic biopsy reports, IHC, and grading.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, and toxicities.\n- Detailed anemia/lymphopenia workup and current performance status.\n- Tumor-level molecular data (somatic NGS, tumor HRD, other predictive markers).\n- PET/FDG or equivalent functional imaging for complete staging.\n\nWorking Plan:\n- Obtain and review complete pathology, operative notes, and oncology treatment history to define diagnosis, stage, and treatment line.\n- Perform targeted evaluation of anemia and lymphopenia and document performance status.\n- Consider PET/FDG for full staging if compatible with goals of care.\n- After clarification of diagnosis, stage, biomarkers, and patient goals, re-discuss systemic and locoregional/palliative options (non‑PARP focused given HRD/BRCA-negative status).\n[R1T1 DELTA] n with current symptoms and performance status. | pathologist->oncologist(missing): Primary histology, IHC panel, and grade remain completely undocumented; please prioritize retrieving original and metastatic biopsy pathology for diagnostic clarification. | pathologist->chair(safety): Key management decisions are being discussed without any confirmed tissue diagnosis; MDT planning should be deferred until pathology reports are obtained and reviewed. | nuclear->oncologist(missing): No PET/FDG has been done; given multifocal liver, pelvic, and bone disease, whole‑body PET could refine current staging and recurrence assessment if results would change management or radiotherapy planning. | nuclear->radiologist(missing): If PET/FDG is obtained, please ensure dedicated pelvic and hepatic assessment to better characterize presacral, hepatic, and iliac bone lesions and detect additional disease.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T19:42:49.595785"}, {"role": "radiologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and probable rectal wall involvement.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no current HRD/BRCA-based options.\n- Staging based only on CT/MR; no PET/FDG performed.\n\nControversies:\n- Primary site, histologic subtype, and grade of the pelvic malignancy remain undefined.\n- Treatment intent and prior systemic therapy lines are unknown, limiting systemic planning.\n- Optimal balance/timing of systemic vs purely palliative/locoregional approaches in the context of cytopenias and metastatic burden is unclear.\n\nMissing Info:\n- Full pathology: primary and recurrent/metastatic biopsy reports, IHC, and grading.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, and toxicities.\n- Detailed anemia/lymphopenia workup and current performance status.\n- Tumor-level molecular data (somatic NGS, tumor HRD, other predictive markers).\n- PET/FDG or equivalent functional imaging for complete staging.\n\nWorking Plan:\n- Obtain and review complete pathology, operative notes, and oncology treatment history to define diagnosis, stage, and treatment line.\n- Perform targeted evaluation of anemia and lymphopenia and document performance status.\n- Consider PET/FDG for full staging if compatible with goals of care.\n- After clarification of diagnosis, stage, biomarkers, and patient goals, re-discuss systemic and locoregional/palliative options (non‑PARP focused given HRD/BRCA-negative status).\n[R1T1 DELTA] n with current symptoms and performance status. | pathologist->oncologist(missing): Primary histology, IHC panel, and grade remain completely undocumented; please prioritize retrieving original and metastatic biopsy pathology for diagnostic clarification. | pathologist->chair(safety): Key management decisions are being discussed without any confirmed tissue diagnosis; MDT planning should be deferred until pathology reports are obtained and reviewed. | nuclear->oncologist(missing): No PET/FDG has been done; given multifocal liver, pelvic, and bone disease, whole‑body PET could refine current staging and recurrence assessment if results would change management or radiotherapy planning. | nuclear->radiologist(missing): If PET/FDG is obtained, please ensure dedicated pelvic and hepatic assessment to better characterize presacral, hepatic, and iliac bone lesions and detect additional disease.\n[R1T2 DELTA] chair->oncologist(safety): Given the absence of any documented tissue diagnosis or prior systemic history, please avoid committing to a specific systemic regimen today and focus on organizing pathology retrieval and anemia/lymphopenia workup. | chair->radiologist(safety): Further local or ablative procedures should not be planned until pathology and oncologic history clarify primary tumor type and intent of care.\n\nProvide FINAL refined plan.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- No new imaging since 2022-12-29; obtain current CT/MR (±PET/FDG) for up-to-date staging and trend. [@2022-12-29|CT][@2022-12-29|MR]  \n\n- Defer planning local/ablative radiologic procedures until pathology, primary tumor type, and treatment intent are clarified. (pathology and history unknown)  \n\n- If PET/FDG performed, ensure whole-body protocol with focused pelvic, hepatic, and right iliac bone assessment for comprehensive disease mapping. (PET/FDG unknown)", "timestamp": "2026-01-18T19:42:59.048101"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and likely rectal wall.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no HRD/BRCA-based options.\n- Staging based on CT/MR only; no PET/FDG performed.\n- Key management decisions are currently being considered without a confirmed tissue diagnosis.\n\nControversies:\n- Primary site, histologic subtype, and grade remain undefined; true origin of pelvic malignancy unclear.\n- Treatment intent and prior systemic therapy lines unknown, limiting systemic and local strategy planning.\n- Appropriateness and timing of systemic vs palliative/locoregional interventions in context of cytopenias and metastatic burden remain uncertain.\n- Whether PET/FDG would meaningfully alter management or radiotherapy planning is not yet established.\n\nMissing Info:\n- Pathology: original and metastatic biopsy reports, full IHC panel, and tumor grade.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, toxicities, and current symptoms/performance status.\n- Hematologic workup for anemia/lymphopenia.\n- Tumor-level molecular profiling (somatic NGS, tumor HRD, predictive markers).\n- PET/FDG or equivalent whole-body functional imaging for comprehensive staging.\n\nWorking Plan:\n- Prioritize retrieval and review of all pathology (primary and metastatic), operative notes, and oncology treatment records before further MDT decision-making.\n- Defer selection of a specific systemic regimen and any local/ablative procedures until diagnosis, primary tumor type, and treatment intent are clarified.\n- Complete workup of anemia and lymphopenia and document current performance status and symptom burden.\n- Consider whole-body PET/FDG, with dedicated pelvic and hepatic assessment, if results are expected to change systemic strategy or radiotherapy planning.\n- Reconvene MDT to reassess systemic and locoregional/palliative options once diagnosis, staging, biomarkers, and goals of care are defined.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T19:43:44.672533"}, {"role": "radiologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and likely rectal wall.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no HRD/BRCA-based options.\n- Staging based on CT/MR only; no PET/FDG performed.\n- Key management decisions are currently being considered without a confirmed tissue diagnosis.\n\nControversies:\n- Primary site, histologic subtype, and grade remain undefined; true origin of pelvic malignancy unclear.\n- Treatment intent and prior systemic therapy lines unknown, limiting systemic and local strategy planning.\n- Appropriateness and timing of systemic vs palliative/locoregional interventions in context of cytopenias and metastatic burden remain uncertain.\n- Whether PET/FDG would meaningfully alter management or radiotherapy planning is not yet established.\n\nMissing Info:\n- Pathology: original and metastatic biopsy reports, full IHC panel, and tumor grade.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, toxicities, and current symptoms/performance status.\n- Hematologic workup for anemia/lymphopenia.\n- Tumor-level molecular profiling (somatic NGS, tumor HRD, predictive markers).\n- PET/FDG or equivalent whole-body functional imaging for comprehensive staging.\n\nWorking Plan:\n- Prioritize retrieval and review of all pathology (primary and metastatic), operative notes, and oncology treatment records before further MDT decision-making.\n- Defer selection of a specific systemic regimen and any local/ablative procedures until diagnosis, primary tumor type, and treatment intent are clarified.\n- Complete workup of anemia and lymphopenia and document current performance status and symptom burden.\n- Consider whole-body PET/FDG, with dedicated pelvic and hepatic assessment, if results are expected to change systemic strategy or radiotherapy planning.\n- Reconvene MDT to reassess systemic and locoregional/palliative options once diagnosis, staging, biomarkers, and goals of care are defined.\n\nProvide FINAL refined plan.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- No imaging newer than 2022-12-29; obtain updated CT/MR (±PET/FDG) for current staging before local procedures. [@2022-12-29|CT][@2022-12-29|MR]  \n\n- Presacral mass with sacral/peritoneal and likely rectal involvement plus progressive liver and iliac bone lesions indicates widespread disease; prioritize palliative intent clarification. [@2022-12-29|MR][@2022-12-29|CT]  \n\n- If PET/FDG pursued, use whole-body protocol with focused pelvic, hepatic, and right iliac bone evaluation to guide radiotherapy/systemic planning. (PET/FDG unknown)", "timestamp": "2026-01-18T19:43:59.775129"}], "pathologist": [{"role": "pathologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- No histology, grade, or IHC available; need primary pathology report and any subsequent biopsies for definitive diagnosis/grading (unknown/needs update).\n\n- Molecular: germline ATM exon8 c.A947G:p.Y316C variant; HRD, BRCA1/2, TP53, ARID1A, PTEN, PIK3CA, PALB2, RAD51D, BRIP1, BARD1 all negative [@OH2203828|2022-04-18].\n\n- Somatic tumor sequencing, HRD status on tumor tissue, and current stage/site of disease not documented; require updated tumor NGS/IHC reports (unknown/needs update).", "timestamp": "2026-01-18T19:42:20.745479"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and probable rectal wall involvement.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no current HRD/BRCA-based options.\n- Staging based only on CT/MR; no PET/FDG performed.\n\nControversies:\n- Primary site, histologic subtype, and grade of the pelvic malignancy remain undefined.\n- Treatment intent and prior systemic therapy lines are unknown, limiting systemic planning.\n- Optimal balance/timing of systemic vs purely palliative/locoregional approaches in the context of cytopenias and metastatic burden is unclear.\n\nMissing Info:\n- Full pathology: primary and recurrent/metastatic biopsy reports, IHC, and grading.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, and toxicities.\n- Detailed anemia/lymphopenia workup and current performance status.\n- Tumor-level molecular data (somatic NGS, tumor HRD, other predictive markers).\n- PET/FDG or equivalent functional imaging for complete staging.\n\nWorking Plan:\n- Obtain and review complete pathology, operative notes, and oncology treatment history to define diagnosis, stage, and treatment line.\n- Perform targeted evaluation of anemia and lymphopenia and document performance status.\n- Consider PET/FDG for full staging if compatible with goals of care.\n- After clarification of diagnosis, stage, biomarkers, and patient goals, re-discuss systemic and locoregional/palliative options (non‑PARP focused given HRD/BRCA-negative status).\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Primary histology, IHC panel, and grade remain completely undocumented; please prioritize retrieving original and metastatic biopsy pathology for diagnostic clarification.\",\"why\":\"missing\"},{\"target\":\"chair\",\"message\":\"Key management decisions are being discussed without any confirmed tissue diagnosis; MDT planning should be deferred until pathology reports are obtained and reviewed.\",\"why\":\"safety\"}]}", "timestamp": "2026-01-18T19:42:42.295864"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and probable rectal wall involvement.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no current HRD/BRCA-based options.\n- Staging based only on CT/MR; no PET/FDG performed.\n\nControversies:\n- Primary site, histologic subtype, and grade of the pelvic malignancy remain undefined.\n- Treatment intent and prior systemic therapy lines are unknown, limiting systemic planning.\n- Optimal balance/timing of systemic vs purely palliative/locoregional approaches in the context of cytopenias and metastatic burden is unclear.\n\nMissing Info:\n- Full pathology: primary and recurrent/metastatic biopsy reports, IHC, and grading.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, and toxicities.\n- Detailed anemia/lymphopenia workup and current performance status.\n- Tumor-level molecular data (somatic NGS, tumor HRD, other predictive markers).\n- PET/FDG or equivalent functional imaging for complete staging.\n\nWorking Plan:\n- Obtain and review complete pathology, operative notes, and oncology treatment history to define diagnosis, stage, and treatment line.\n- Perform targeted evaluation of anemia and lymphopenia and document performance status.\n- Consider PET/FDG for full staging if compatible with goals of care.\n- After clarification of diagnosis, stage, biomarkers, and patient goals, re-discuss systemic and locoregional/palliative options (non‑PARP focused given HRD/BRCA-negative status).\n[R1T1 DELTA] n with current symptoms and performance status. | pathologist->oncologist(missing): Primary histology, IHC panel, and grade remain completely undocumented; please prioritize retrieving original and metastatic biopsy pathology for diagnostic clarification. | pathologist->chair(safety): Key management decisions are being discussed without any confirmed tissue diagnosis; MDT planning should be deferred until pathology reports are obtained and reviewed. | nuclear->oncologist(missing): No PET/FDG has been done; given multifocal liver, pelvic, and bone disease, whole‑body PET could refine current staging and recurrence assessment if results would change management or radiotherapy planning. | nuclear->radiologist(missing): If PET/FDG is obtained, please ensure dedicated pelvic and hepatic assessment to better characterize presacral, hepatic, and iliac bone lesions and detect additional disease.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T19:42:50.965778"}, {"role": "pathologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and probable rectal wall involvement.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no current HRD/BRCA-based options.\n- Staging based only on CT/MR; no PET/FDG performed.\n\nControversies:\n- Primary site, histologic subtype, and grade of the pelvic malignancy remain undefined.\n- Treatment intent and prior systemic therapy lines are unknown, limiting systemic planning.\n- Optimal balance/timing of systemic vs purely palliative/locoregional approaches in the context of cytopenias and metastatic burden is unclear.\n\nMissing Info:\n- Full pathology: primary and recurrent/metastatic biopsy reports, IHC, and grading.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, and toxicities.\n- Detailed anemia/lymphopenia workup and current performance status.\n- Tumor-level molecular data (somatic NGS, tumor HRD, other predictive markers).\n- PET/FDG or equivalent functional imaging for complete staging.\n\nWorking Plan:\n- Obtain and review complete pathology, operative notes, and oncology treatment history to define diagnosis, stage, and treatment line.\n- Perform targeted evaluation of anemia and lymphopenia and document performance status.\n- Consider PET/FDG for full staging if compatible with goals of care.\n- After clarification of diagnosis, stage, biomarkers, and patient goals, re-discuss systemic and locoregional/palliative options (non‑PARP focused given HRD/BRCA-negative status).\n[R1T1 DELTA] n with current symptoms and performance status. | pathologist->oncologist(missing): Primary histology, IHC panel, and grade remain completely undocumented; please prioritize retrieving original and metastatic biopsy pathology for diagnostic clarification. | pathologist->chair(safety): Key management decisions are being discussed without any confirmed tissue diagnosis; MDT planning should be deferred until pathology reports are obtained and reviewed. | nuclear->oncologist(missing): No PET/FDG has been done; given multifocal liver, pelvic, and bone disease, whole‑body PET could refine current staging and recurrence assessment if results would change management or radiotherapy planning. | nuclear->radiologist(missing): If PET/FDG is obtained, please ensure dedicated pelvic and hepatic assessment to better characterize presacral, hepatic, and iliac bone lesions and detect additional disease.\n[R1T2 DELTA] chair->oncologist(safety): Given the absence of any documented tissue diagnosis or prior systemic history, please avoid committing to a specific systemic regimen today and focus on organizing pathology retrieval and anemia/lymphopenia workup. | chair->radiologist(safety): Further local or ablative procedures should not be planned until pathology and oncologic history clarify primary tumor type and intent of care.\n\nProvide FINAL refined plan.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Retrieve and review all prior pathology (primary and metastatic), IHC, and grading to establish definitive diagnosis (currently unknown/needs update).  \n\n- After diagnosis confirmation, obtain tumor-level molecular testing (somatic NGS, tumor HRD, other markers) if tissue and performance status allow (unknown/needs update).  \n\n- Defer commitment to specific systemic strategies until pathology, oncologic history, and cytopenia workup are clarified and formally documented (unknown/needs update).", "timestamp": "2026-01-18T19:43:01.232354"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and likely rectal wall.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no HRD/BRCA-based options.\n- Staging based on CT/MR only; no PET/FDG performed.\n- Key management decisions are currently being considered without a confirmed tissue diagnosis.\n\nControversies:\n- Primary site, histologic subtype, and grade remain undefined; true origin of pelvic malignancy unclear.\n- Treatment intent and prior systemic therapy lines unknown, limiting systemic and local strategy planning.\n- Appropriateness and timing of systemic vs palliative/locoregional interventions in context of cytopenias and metastatic burden remain uncertain.\n- Whether PET/FDG would meaningfully alter management or radiotherapy planning is not yet established.\n\nMissing Info:\n- Pathology: original and metastatic biopsy reports, full IHC panel, and tumor grade.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, toxicities, and current symptoms/performance status.\n- Hematologic workup for anemia/lymphopenia.\n- Tumor-level molecular profiling (somatic NGS, tumor HRD, predictive markers).\n- PET/FDG or equivalent whole-body functional imaging for comprehensive staging.\n\nWorking Plan:\n- Prioritize retrieval and review of all pathology (primary and metastatic), operative notes, and oncology treatment records before further MDT decision-making.\n- Defer selection of a specific systemic regimen and any local/ablative procedures until diagnosis, primary tumor type, and treatment intent are clarified.\n- Complete workup of anemia and lymphopenia and document current performance status and symptom burden.\n- Consider whole-body PET/FDG, with dedicated pelvic and hepatic assessment, if results are expected to change systemic strategy or radiotherapy planning.\n- Reconvene MDT to reassess systemic and locoregional/palliative options once diagnosis, staging, biomarkers, and goals of care are defined.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T19:43:46.081986"}, {"role": "pathologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and likely rectal wall.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no HRD/BRCA-based options.\n- Staging based on CT/MR only; no PET/FDG performed.\n- Key management decisions are currently being considered without a confirmed tissue diagnosis.\n\nControversies:\n- Primary site, histologic subtype, and grade remain undefined; true origin of pelvic malignancy unclear.\n- Treatment intent and prior systemic therapy lines unknown, limiting systemic and local strategy planning.\n- Appropriateness and timing of systemic vs palliative/locoregional interventions in context of cytopenias and metastatic burden remain uncertain.\n- Whether PET/FDG would meaningfully alter management or radiotherapy planning is not yet established.\n\nMissing Info:\n- Pathology: original and metastatic biopsy reports, full IHC panel, and tumor grade.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, toxicities, and current symptoms/performance status.\n- Hematologic workup for anemia/lymphopenia.\n- Tumor-level molecular profiling (somatic NGS, tumor HRD, predictive markers).\n- PET/FDG or equivalent whole-body functional imaging for comprehensive staging.\n\nWorking Plan:\n- Prioritize retrieval and review of all pathology (primary and metastatic), operative notes, and oncology treatment records before further MDT decision-making.\n- Defer selection of a specific systemic regimen and any local/ablative procedures until diagnosis, primary tumor type, and treatment intent are clarified.\n- Complete workup of anemia and lymphopenia and document current performance status and symptom burden.\n- Consider whole-body PET/FDG, with dedicated pelvic and hepatic assessment, if results are expected to change systemic strategy or radiotherapy planning.\n- Reconvene MDT to reassess systemic and locoregional/palliative options once diagnosis, staging, biomarkers, and goals of care are defined.\n\nProvide FINAL refined plan.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Retrieve and review all primary/metastatic pathology reports, IHC, and grading to establish definitive diagnosis (currently unknown/needs update).  \n\n- After diagnosis confirmation, perform tumor-level molecular profiling (somatic NGS, tumor HRD, predictive markers) if tissue available (unknown/needs update).  \n\n- Reconvene MDT to align staging and biomarker data with clarified goals of care before systemic or locoregional decisions (unknown/needs update).", "timestamp": "2026-01-18T19:44:02.015682"}], "nuclear": [{"role": "nuclear", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- No PET/FDG study available; metabolic pattern, staging impact, and recurrence assessment are currently unknown/needs update.\n\n- Cross‑sectional imaging shows progressive multifocal hepatic lesions, highly suspicious for metastases, but without metabolic characterization [@2022-10-24|CT][@2022-12-29|CT].\n\n- Pelvic MR shows enlarging presacral mass with adjacent bone/peritoneal involvement, compatible with local recurrence and metastasis, pending PET correlation [@2022-12-29|MR].", "timestamp": "2026-01-18T19:42:22.895600"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and probable rectal wall involvement.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no current HRD/BRCA-based options.\n- Staging based only on CT/MR; no PET/FDG performed.\n\nControversies:\n- Primary site, histologic subtype, and grade of the pelvic malignancy remain undefined.\n- Treatment intent and prior systemic therapy lines are unknown, limiting systemic planning.\n- Optimal balance/timing of systemic vs purely palliative/locoregional approaches in the context of cytopenias and metastatic burden is unclear.\n\nMissing Info:\n- Full pathology: primary and recurrent/metastatic biopsy reports, IHC, and grading.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, and toxicities.\n- Detailed anemia/lymphopenia workup and current performance status.\n- Tumor-level molecular data (somatic NGS, tumor HRD, other predictive markers).\n- PET/FDG or equivalent functional imaging for complete staging.\n\nWorking Plan:\n- Obtain and review complete pathology, operative notes, and oncology treatment history to define diagnosis, stage, and treatment line.\n- Perform targeted evaluation of anemia and lymphopenia and document performance status.\n- Consider PET/FDG for full staging if compatible with goals of care.\n- After clarification of diagnosis, stage, biomarkers, and patient goals, re-discuss systemic and locoregional/palliative options (non‑PARP focused given HRD/BRCA-negative status).\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"No PET/FDG has been done; given multifocal liver, pelvic, and bone disease, whole‑body PET could refine current staging and recurrence assessment if results would change management or radiotherapy planning.\",\"why\":\"missing\"},{\"target\":\"radiologist\",\"message\":\"If PET/FDG is obtained, please ensure dedicated pelvic and hepatic assessment to better characterize presacral, hepatic, and iliac bone lesions and detect additional disease.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T19:42:44.436161"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and probable rectal wall involvement.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no current HRD/BRCA-based options.\n- Staging based only on CT/MR; no PET/FDG performed.\n\nControversies:\n- Primary site, histologic subtype, and grade of the pelvic malignancy remain undefined.\n- Treatment intent and prior systemic therapy lines are unknown, limiting systemic planning.\n- Optimal balance/timing of systemic vs purely palliative/locoregional approaches in the context of cytopenias and metastatic burden is unclear.\n\nMissing Info:\n- Full pathology: primary and recurrent/metastatic biopsy reports, IHC, and grading.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, and toxicities.\n- Detailed anemia/lymphopenia workup and current performance status.\n- Tumor-level molecular data (somatic NGS, tumor HRD, other predictive markers).\n- PET/FDG or equivalent functional imaging for complete staging.\n\nWorking Plan:\n- Obtain and review complete pathology, operative notes, and oncology treatment history to define diagnosis, stage, and treatment line.\n- Perform targeted evaluation of anemia and lymphopenia and document performance status.\n- Consider PET/FDG for full staging if compatible with goals of care.\n- After clarification of diagnosis, stage, biomarkers, and patient goals, re-discuss systemic and locoregional/palliative options (non‑PARP focused given HRD/BRCA-negative status).\n[R1T1 DELTA] n with current symptoms and performance status. | pathologist->oncologist(missing): Primary histology, IHC panel, and grade remain completely undocumented; please prioritize retrieving original and metastatic biopsy pathology for diagnostic clarification. | pathologist->chair(safety): Key management decisions are being discussed without any confirmed tissue diagnosis; MDT planning should be deferred until pathology reports are obtained and reviewed. | nuclear->oncologist(missing): No PET/FDG has been done; given multifocal liver, pelvic, and bone disease, whole‑body PET could refine current staging and recurrence assessment if results would change management or radiotherapy planning. | nuclear->radiologist(missing): If PET/FDG is obtained, please ensure dedicated pelvic and hepatic assessment to better characterize presacral, hepatic, and iliac bone lesions and detect additional disease.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T19:42:52.306390"}, {"role": "nuclear", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and probable rectal wall involvement.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no current HRD/BRCA-based options.\n- Staging based only on CT/MR; no PET/FDG performed.\n\nControversies:\n- Primary site, histologic subtype, and grade of the pelvic malignancy remain undefined.\n- Treatment intent and prior systemic therapy lines are unknown, limiting systemic planning.\n- Optimal balance/timing of systemic vs purely palliative/locoregional approaches in the context of cytopenias and metastatic burden is unclear.\n\nMissing Info:\n- Full pathology: primary and recurrent/metastatic biopsy reports, IHC, and grading.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, and toxicities.\n- Detailed anemia/lymphopenia workup and current performance status.\n- Tumor-level molecular data (somatic NGS, tumor HRD, other predictive markers).\n- PET/FDG or equivalent functional imaging for complete staging.\n\nWorking Plan:\n- Obtain and review complete pathology, operative notes, and oncology treatment history to define diagnosis, stage, and treatment line.\n- Perform targeted evaluation of anemia and lymphopenia and document performance status.\n- Consider PET/FDG for full staging if compatible with goals of care.\n- After clarification of diagnosis, stage, biomarkers, and patient goals, re-discuss systemic and locoregional/palliative options (non‑PARP focused given HRD/BRCA-negative status).\n[R1T1 DELTA] n with current symptoms and performance status. | pathologist->oncologist(missing): Primary histology, IHC panel, and grade remain completely undocumented; please prioritize retrieving original and metastatic biopsy pathology for diagnostic clarification. | pathologist->chair(safety): Key management decisions are being discussed without any confirmed tissue diagnosis; MDT planning should be deferred until pathology reports are obtained and reviewed. | nuclear->oncologist(missing): No PET/FDG has been done; given multifocal liver, pelvic, and bone disease, whole‑body PET could refine current staging and recurrence assessment if results would change management or radiotherapy planning. | nuclear->radiologist(missing): If PET/FDG is obtained, please ensure dedicated pelvic and hepatic assessment to better characterize presacral, hepatic, and iliac bone lesions and detect additional disease.\n[R1T2 DELTA] chair->oncologist(safety): Given the absence of any documented tissue diagnosis or prior systemic history, please avoid committing to a specific systemic regimen today and focus on organizing pathology retrieval and anemia/lymphopenia workup. | chair->radiologist(safety): Further local or ablative procedures should not be planned until pathology and oncologic history clarify primary tumor type and intent of care.\n\nProvide FINAL refined plan.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Recommend whole‑body FDG PET/CT to clarify metabolic burden, confirm recurrence, and assess liver, presacral, and iliac bone lesions [@2022-10-24|CT][@2022-12-29|MR][@2022-12-29|CT].  \n\n- If PET/CT performed, ensure high‑resolution pelvic and hepatic imaging to guide potential radiotherapy fields and avoid missing additional metastases [@2022-12-29|MR][@2022-12-29|CT].  \n\n- PET findings should be integrated with pending pathology and clinical status before altering staging or committing to further locoregional interventions (pathology/PS currently unknown).", "timestamp": "2026-01-18T19:43:17.559282"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and likely rectal wall.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no HRD/BRCA-based options.\n- Staging based on CT/MR only; no PET/FDG performed.\n- Key management decisions are currently being considered without a confirmed tissue diagnosis.\n\nControversies:\n- Primary site, histologic subtype, and grade remain undefined; true origin of pelvic malignancy unclear.\n- Treatment intent and prior systemic therapy lines unknown, limiting systemic and local strategy planning.\n- Appropriateness and timing of systemic vs palliative/locoregional interventions in context of cytopenias and metastatic burden remain uncertain.\n- Whether PET/FDG would meaningfully alter management or radiotherapy planning is not yet established.\n\nMissing Info:\n- Pathology: original and metastatic biopsy reports, full IHC panel, and tumor grade.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, toxicities, and current symptoms/performance status.\n- Hematologic workup for anemia/lymphopenia.\n- Tumor-level molecular profiling (somatic NGS, tumor HRD, predictive markers).\n- PET/FDG or equivalent whole-body functional imaging for comprehensive staging.\n\nWorking Plan:\n- Prioritize retrieval and review of all pathology (primary and metastatic), operative notes, and oncology treatment records before further MDT decision-making.\n- Defer selection of a specific systemic regimen and any local/ablative procedures until diagnosis, primary tumor type, and treatment intent are clarified.\n- Complete workup of anemia and lymphopenia and document current performance status and symptom burden.\n- Consider whole-body PET/FDG, with dedicated pelvic and hepatic assessment, if results are expected to change systemic strategy or radiotherapy planning.\n- Reconvene MDT to reassess systemic and locoregional/palliative options once diagnosis, staging, biomarkers, and goals of care are defined.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T19:43:51.008223"}, {"role": "nuclear", "user_message": "Given MDT context:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and likely rectal wall.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no HRD/BRCA-based options.\n- Staging based on CT/MR only; no PET/FDG performed.\n- Key management decisions are currently being considered without a confirmed tissue diagnosis.\n\nControversies:\n- Primary site, histologic subtype, and grade remain undefined; true origin of pelvic malignancy unclear.\n- Treatment intent and prior systemic therapy lines unknown, limiting systemic and local strategy planning.\n- Appropriateness and timing of systemic vs palliative/locoregional interventions in context of cytopenias and metastatic burden remain uncertain.\n- Whether PET/FDG would meaningfully alter management or radiotherapy planning is not yet established.\n\nMissing Info:\n- Pathology: original and metastatic biopsy reports, full IHC panel, and tumor grade.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, toxicities, and current symptoms/performance status.\n- Hematologic workup for anemia/lymphopenia.\n- Tumor-level molecular profiling (somatic NGS, tumor HRD, predictive markers).\n- PET/FDG or equivalent whole-body functional imaging for comprehensive staging.\n\nWorking Plan:\n- Prioritize retrieval and review of all pathology (primary and metastatic), operative notes, and oncology treatment records before further MDT decision-making.\n- Defer selection of a specific systemic regimen and any local/ablative procedures until diagnosis, primary tumor type, and treatment intent are clarified.\n- Complete workup of anemia and lymphopenia and document current performance status and symptom burden.\n- Consider whole-body PET/FDG, with dedicated pelvic and hepatic assessment, if results are expected to change systemic strategy or radiotherapy planning.\n- Reconvene MDT to reassess systemic and locoregional/palliative options once diagnosis, staging, biomarkers, and goals of care are defined.\n\nProvide FINAL refined plan.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- No PET/FDG has been performed; metabolic tumor burden, recurrence confirmation, and PET-based staging remain unknown/needs update (CT/MR only) [@2022-12-29|MR][@2022-12-29|CT].  \n\n- If obtained, whole‑body FDG PET/CT could better define liver, presacral, and right iliac bone involvement and detect occult disease [@2022-10-24|CT][@2022-12-29|MR][@2022-12-29|CT].  \n\n- PET findings should be interpreted jointly with pending pathology and performance status before changing radiotherapy fields or overall staging (pathology/PS currently unknown).", "timestamp": "2026-01-18T19:44:21.707929"}], "assistant": [{"role": "assistant", "user_message": "Summarize expert opinions concisely for MDT.\n{\"chair\":\"- Advanced recurrent pelvic malignancy with progressive liver and bone metastases; clarify primary site, histology, and prior treatments before systemic strategy.  \\n\\n- Marked anemia and lymphopenia; urgently evaluate etiology, bleeding, iron/B12/folate, hemolysis, and performance status before intensive therapy. [@20230103|2023-01-03]  \\n\\n- HRD negative, BRCA wild-type; consider non‑PARP systemic/locoregional options once pathology, stage, symptoms, and goals of care are updated. [@OH2203828|2022-04-18]\",\"oncologist\":\"- Diagnosis, stage, prior systemic therapy line, and treatment intent are all unknown/needs update before any regimen choice.  \\n\\n- Current labs show significant anemia with preserved platelets and renal/liver function, affecting intensity and timing of systemic therapy [@20221229|8300002][@20230103|5600862].  \\n\\n- Germline testing: HRD negative, no pathogenic BRCA1/2 or other listed DNA-repair mutations; influences maintenance/targeted strategy selection [@OH2203828|2022-04-18].\",\"radiologist\":\"- Liver: multiple low-density metastases, increased number and size versus 2022-10-24; largest ~17×14 mm. [@2022-10-24|CT][@2022-12-29|CT]\\n\\n- Pelvis: presacral mass ~53×44 mm with heterogeneous enhancement, involving adjacent peritoneum and sacrum; pelvic mesenteric nodules. [@2022-12-29|MR]\\n\\n- New right iliac bone enhancing lesion suggesting osseous metastasis; rectal wall thickening/enhancement may indicate local invasion. [@2022-12-29|MR]\",\"pathologist\":\"- No histology, grade, or IHC available; need primary pathology report and any subsequent biopsies for definitive diagnosis/grading (unknown/needs update).\\n\\n- Molecular: germline ATM exon8 c.A947G:p.Y316C variant; HRD, BRCA1/2, TP53, ARID1A, PTEN, PIK3CA, PALB2, RAD51D, BRIP1, BARD1 all negative [@OH2203828|2022-04-18].\\n\\n- Somatic tumor sequencing, HRD status on tumor tissue, and current stage/site of disease not documented; require updated tumor NGS/IHC reports (unknown/needs update).\",\"nuclear\":\"- No PET/FDG study available; metabolic pattern, staging impact, and recurrence assessment are currently unknown/needs update.\\n\\n- Cross‑sectional imaging shows progressive multifocal hepatic lesions, highly suspicious for metastases, but without metabolic characterization [@2022-10-24|CT][@2022-12-29|CT].\\n\\n- Pelvic MR shows enlarging presacral mass with adjacent bone/peritoneal involvement, compatible with local recurrence and metastasis, pending PET correlation [@2022-12-29|MR].\"}\n\nOutput:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass involving sacrum/peritoneum and pelvic mesentery; rectal wall thickening suggests local invasion.\n- Progressive metastatic disease: multiple increasing liver metastases and new right iliac bone lesion.\n- Significant anemia and lymphopenia with otherwise preserved platelets and organ function.\n- HRD negative, BRCA wild-type; germline ATM variant of unclear significance; no actionable HRD/BRCA mutations identified.\n- No PET/FDG imaging performed; current staging based on CT/MR only.\n\nControversies:\n- Primary site, histologic subtype, and tumor grade are not documented; true origin of “pelvic malignancy” unclear.\n- Treatment intent (curative vs palliative) and line of prior systemic therapy not specified, limiting systemic strategy selection.\n- Role and timing of systemic therapy vs locoregional/palliative approaches in the context of anemia, lymphopenia, and metastatic burden remain undefined.\n\nMissing Info:\n- Definitive pathology: primary report, histology, grade, full IHC, and any biopsy from recurrent/metastatic sites.\n- Complete oncologic history: initial stage, previous surgery/radiotherapy/systemic regimens and responses, current performance status, and goals of care.\n- Full anemia/lymphopenia workup: bleeding source, iron/B12/folate status, hemolysis, bone marrow involvement, or other causes.\n- Tumor-based molecular data: somatic NGS, tumor HRD status, and any predictive biomarkers.\n- Functional imaging: PET/FDG for metabolic staging and assessment of disease extent.\n\nWorking Plan:\n- Retrieve and review all prior pathology, operative, and oncology treatment records to define primary site, histology, grade, stage, and treatment line.\n- Complete hematologic evaluation of anemia and lymphopenia and assess performance status before considering intensive systemic therapy.\n- Consider PET/FDG for comprehensive staging and to clarify extent of local recurrence and systemic disease, if aligned with goals of care.\n- Reassess systemic and locoregional options in the context of HRD/BRCA-negative status once diagnosis, staging, symptoms, and patient preferences are updated.", "timestamp": "2026-01-18T19:42:27.559771"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass involving sacrum/peritoneum and pelvic mesentery; rectal wall thickening suggests local invasion.\n- Progressive metastatic disease: multiple increasing liver metastases and new right iliac bone lesion.\n- Significant anemia and lymphopenia with otherwise preserved platelets and organ function.\n- HRD negative, BRCA wild-type; germline ATM variant of unclear significance; no actionable HRD/BRCA mutations identified.\n- No PET/FDG imaging performed; current staging based on CT/MR only.\n\nControversies:\n- Primary site, histologic subtype, and tumor grade are not documented; true origin of “pelvic malignancy” unclear.\n- Treatment intent (curative vs palliative) and line of prior systemic therapy not specified, limiting systemic strategy selection.\n- Role and timing of systemic therapy vs locoregional/palliative approaches in the context of anemia, lymphopenia, and metastatic burden remain undefined.\n\nMissing Info:\n- Definitive pathology: primary report, histology, grade, full IHC, and any biopsy from recurrent/metastatic sites.\n- Complete oncologic history: initial stage, previous surgery/radiotherapy/systemic regimens and responses, current performance status, and goals of care.\n- Full anemia/lymphopenia workup: bleeding source, iron/B12/folate status, hemolysis, bone marrow involvement, or other causes.\n- Tumor-based molecular data: somatic NGS, tumor HRD status, and any predictive biomarkers.\n- Functional imaging: PET/FDG for metabolic staging and assessment of disease extent.\n\nWorking Plan:\n- Retrieve and review all prior pathology, operative, and oncology treatment records to define primary site, histology, grade, stage, and treatment line.\n- Complete hematologic evaluation of anemia and lymphopenia and assess performance status before considering intensive systemic therapy.\n- Consider PET/FDG for comprehensive staging and to clarify extent of local recurrence and systemic disease, if aligned with goals of care.\n- Reassess systemic and locoregional options in the context of HRD/BRCA-negative status once diagnosis, staging, symptoms, and patient preferences are updated.\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and probable rectal wall involvement.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no current HRD/BRCA-based options.\n- Staging based only on CT/MR; no PET/FDG performed.\n\nControversies:\n- Primary site, histologic subtype, and grade of the pelvic malignancy remain undefined.\n- Treatment intent and prior systemic therapy lines are unknown, limiting systemic planning.\n- Optimal balance/timing of systemic vs purely palliative/locoregional approaches in the context of cytopenias and metastatic burden is unclear.\n\nMissing Info:\n- Full pathology: primary and recurrent/metastatic biopsy reports, IHC, and grading.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, and toxicities.\n- Detailed anemia/lymphopenia workup and current performance status.\n- Tumor-level molecular data (somatic NGS, tumor HRD, other predictive markers).\n- PET/FDG or equivalent functional imaging for complete staging.\n\nWorking Plan:\n- Obtain and review complete pathology, operative notes, and oncology treatment history to define diagnosis, stage, and treatment line.\n- Perform targeted evaluation of anemia and lymphopenia and document performance status.\n- Consider PET/FDG for full staging if compatible with goals of care.\n- After clarification of diagnosis, stage, biomarkers, and patient goals, re-discuss systemic and locoregional/palliative options (non‑PARP focused given HRD/BRCA-negative status).", "timestamp": "2026-01-18T19:42:33.614117"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and probable rectal wall involvement.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no current HRD/BRCA-based options.\n- Staging based only on CT/MR; no PET/FDG performed.\n\nControversies:\n- Primary site, histologic subtype, and grade of the pelvic malignancy remain undefined.\n- Treatment intent and prior systemic therapy lines are unknown, limiting systemic planning.\n- Optimal balance/timing of systemic vs purely palliative/locoregional approaches in the context of cytopenias and metastatic burden is unclear.\n\nMissing Info:\n- Full pathology: primary and recurrent/metastatic biopsy reports, IHC, and grading.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, and toxicities.\n- Detailed anemia/lymphopenia workup and current performance status.\n- Tumor-level molecular data (somatic NGS, tumor HRD, other predictive markers).\n- PET/FDG or equivalent functional imaging for complete staging.\n\nWorking Plan:\n- Obtain and review complete pathology, operative notes, and oncology treatment history to define diagnosis, stage, and treatment line.\n- Perform targeted evaluation of anemia and lymphopenia and document performance status.\n- Consider PET/FDG for full staging if compatible with goals of care.\n- After clarification of diagnosis, stage, biomarkers, and patient goals, re-discuss systemic and locoregional/palliative options (non‑PARP focused given HRD/BRCA-negative status).\n[R1T1 DELTA] n with current symptoms and performance status. | pathologist->oncologist(missing): Primary histology, IHC panel, and grade remain completely undocumented; please prioritize retrieving original and metastatic biopsy pathology for diagnostic clarification. | pathologist->chair(safety): Key management decisions are being discussed without any confirmed tissue diagnosis; MDT planning should be deferred until pathology reports are obtained and reviewed. | nuclear->oncologist(missing): No PET/FDG has been done; given multifocal liver, pelvic, and bone disease, whole‑body PET could refine current staging and recurrence assessment if results would change management or radiotherapy planning. | nuclear->radiologist(missing): If PET/FDG is obtained, please ensure dedicated pelvic and hepatic assessment to better characterize presacral, hepatic, and iliac bone lesions and detect additional disease.\n[R1T2 DELTA] chair->oncologist(safety): Given the absence of any documented tissue diagnosis or prior systemic history, please avoid committing to a specific systemic regimen today and focus on organizing pathology retrieval and anemia/lymphopenia workup. | chair->radiologist(safety): Further local or ablative procedures should not be planned until pathology and oncologic history clarify primary tumor type and intent of care.\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Advanced recurrent pelvic malignancy with enlarging presacral mass invading sacrum/peritoneum and likely rectal wall.\n- Progressive metastases: increasing liver lesions and new right iliac bone lesion.\n- Marked anemia and lymphopenia; platelets and renal/hepatic function relatively preserved.\n- HRD negative, BRCA wild-type; germline ATM variant of uncertain significance; no HRD/BRCA-based options.\n- Staging based on CT/MR only; no PET/FDG performed.\n- Key management decisions are currently being considered without a confirmed tissue diagnosis.\n\nControversies:\n- Primary site, histologic subtype, and grade remain undefined; true origin of pelvic malignancy unclear.\n- Treatment intent and prior systemic therapy lines unknown, limiting systemic and local strategy planning.\n- Appropriateness and timing of systemic vs palliative/locoregional interventions in context of cytopenias and metastatic burden remain uncertain.\n- Whether PET/FDG would meaningfully alter management or radiotherapy planning is not yet established.\n\nMissing Info:\n- Pathology: original and metastatic biopsy reports, full IHC panel, and tumor grade.\n- Oncologic history: initial stage, prior surgery/radiation/systemic therapies, responses, toxicities, and current symptoms/performance status.\n- Hematologic workup for anemia/lymphopenia.\n- Tumor-level molecular profiling (somatic NGS, tumor HRD, predictive markers).\n- PET/FDG or equivalent whole-body functional imaging for comprehensive staging.\n\nWorking Plan:\n- Prioritize retrieval and review of all pathology (primary and metastatic), operative notes, and oncology treatment records before further MDT decision-making.\n- Defer selection of a specific systemic regimen and any local/ablative procedures until diagnosis, primary tumor type, and treatment intent are clarified.\n- Complete workup of anemia and lymphopenia and document current performance status and symptom burden.\n- Consider whole-body PET/FDG, with dedicated pelvic and hepatic assessment, if results are expected to change systemic strategy or radiotherapy planning.\n- Reconvene MDT to reassess systemic and locoregional/palliative options once diagnosis, staging, biomarkers, and goals of care are defined.", "timestamp": "2026-01-18T19:43:22.287463"}]}, "trace_events": [{"ts": "2026-01-18T19:41:36.539507", "event": "pipeline_start", "payload": {"visit_time": "2023-01-03 08:53:29.260000", "meta_info": "340123197709263626"}}, {"ts": "2026-01-18T19:41:36.539758", "event": "case_fingerprint", "payload": {"case_fingerprint": "bf21a9e8fbc5"}}, {"ts": "2026-01-18T19:41:37.100561", "event": "reports_loaded", "payload": {"lab_n": 92, "img_n": 10, "path_n": 0, "mut_n": 1, "cutoff_dt": "2023-01-04 08:53:29"}}, {"ts": "2026-01-18T19:41:47.773534", "event": "reports_selected", "payload": {"lab": {"chair": ["20221229|8300002|2022-12-29", "20221229|9703212|2022-12-29", "20230103|5600862|2023-01-03"], "oncologist": ["20221229|8300002|2022-12-29", "20221229|9703212|2022-12-29", "20230103|5600862|2023-01-03"], "radiologist": [], "pathologist": [], "nuclear": []}, "imaging": {"chair": ["2022-10-24|CT|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"], "oncologist": [], "radiologist": ["2022-10-24|CT|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"], "pathologist": [], "nuclear": ["2022-10-24|CT|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"]}, "pathology": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "mutation": {"chair": ["OH2203828|2022-04-18"], "oncologist": ["OH2203828|2022-04-18"], "radiologist": [], "pathologist": ["OH2203828|2022-04-18"], "nuclear": []}}}, {"ts": "2026-01-18T19:42:06.465499", "event": "rag_query", "payload": {"query": "Guidelines for treatment of ovarian cancer by histology and platinum sensitivity, considering disease stage/metastatic spread, BRCA/HRD/MSI/PD-L1/ATM status if available, and management in the context of performance status, anemia, and organ function limitations."}}, {"ts": "2026-01-18T19:42:06.465527", "event": "rag_hits", "payload": {"source": "guideline", "topk": 5, "n": 5}}, {"ts": "2026-01-18T19:42:06.465531", "event": "rag_hits", "payload": {"source": "pubmed", "topk": 5, "n": 5}}, {"ts": "2026-01-18T19:42:06.465534", "event": "rag_hits_merged", "payload": {"n": 10}}, {"ts": "2026-01-18T19:42:11.481091", "event": "mdt_discussion_start", "payload": {"num_rounds": 2, "num_turns": 2}}, {"ts": "2026-01-18T19:42:13.754365", "event": "evidence_tag_warning", "payload": {"role": "chair/initial", "preview": "- Advanced recurrent pelvic malignancy with progressive liver and bone metastases; clarify primary site, histology, and prior treatments before systemic strateg…"}}, {"ts": "2026-01-18T19:42:16.070242", "event": "evidence_tag_warning", "payload": {"role": "oncologist/initial", "preview": "- Diagnosis, stage, prior systemic therapy line, and treatment intent are all unknown/needs update before any regimen choice.    - Current labs show significant…"}}, {"ts": "2026-01-18T19:42:22.895718", "event": "evidence_tag_warning", "payload": {"role": "nuclear/initial", "preview": "- No PET/FDG study available; metabolic pattern, staging impact, and recurrence assessment are currently unknown/needs update.  - Cross‑sectional imaging shows …"}}, {"ts": "2026-01-18T19:44:21.708075", "event": "mdt_discussion_end", "payload": {"merged_chars": 2229}}, {"ts": "2026-01-18T19:44:21.709286", "event": "final_output_start", "payload": {}}, {"ts": "2026-01-18T19:44:40.410825", "event": "final_output_end", "payload": {"final_output_chars": 1422}}], "trace_mermaid": "flowchart TD\n  A[Load Case + Fingerprint] --> B[Load Reports]\n  B --> C[Report Selection per Role]\n  C --> D[Guideline+PubMed RAG]\n  D --> E[Init Specialist Agents]\n  E --> F[MDT Discussion Engine]\n  F --> G[Trial Matching]\n  G --> H[Final Chair Output]\n  H --> I[Save Logs]\n"}
